Navigation Links
Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
Date:5/18/2009

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

About Oak Investment Partners

Oak Investment Partners is a multi-stage venture capital firm with a total of $8.4 billion in committed capital. The primary investment focus is on high growth opportunities in Healthcare Information and Services, Information Technology and Software Outsourced Services, Consumer Internet/New Media, Financial Services Technology, Clean Energy, Broadband Internet and Wireless Communications, and Retail. Over a 30-year history, Oak has achieved a strong track record as a stage-independent investor funding more than 481 companies at key points in their lifecycles. Oak has been involved in the formation of companies, funded spinouts of operating divisions and technology assets, and provided growth equity to mid- and late-stage private businesses
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
2. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
3. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
4. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
5. Jim Agnello to Resign as Clarient Chief Financial Officer
6. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Clarient to Commercialize Novel Breast Cancer Profile
9. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
10. Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
11. NovImmune Completes CHF 62.5 (USD 54.8) Million Equity Financing to Move Portfolio Forward and Reacquire Product Rights to Lead Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Brady ... GHS Label Guide . To align chemical container labeling with OSHA’s updated ... explanations of label components, an example of an accurate label, and pictogram uses ...
(Date:7/29/2015)... YORK , July 29, 2015  Therapath ... testing, announces increased partnerships with VA and Military ... Epidermal Nerve Fiber Density (ENFD) and Sweat Gland ... small fiber neuropathy ( https://therapath.com/skin ). ... Nerve Fiber Density (ENFD) on punch skin biopsy ...
(Date:7/29/2015)... SLOUGH, England , July 29, 2015  Indivior ... Application (NDA) for naloxone nasal spray was accepted and ... Administration (FDA) for the treatment of opioid overdose. This ... contains naloxone specially formulated for optimal absorption into the ... to require minimal training so individuals may be better ...
(Date:7/29/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... to announce that the final design specifications of ... Prototypes for industrial and regulatory testing will now ... CE mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The ...
Breaking Biology Technology:Brady Announces a New GHS Label Guide 2Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... Delcath Systems, Inc. (Nasdaq: DCTH ), ... Perfusion ("PHP") System for the treatment of cancers of the ... 92) of patients have been enrolled in the Phase III ... liver. The eleven participating cancer centers in this trial ...
... India, December 11 , - SCRIP Awards Recognises ... and Biotech Industries Worldwide, - Glenmark is ... Prestigious Recognition, , ... at a glittering ceremony in London at the 2008 SCRIP Awards ...
... Board to Take Immediate Action to Protect and Maximize Shareholder Value ... Biotechnology Value Fund, L.P., the owner, together with its affiliates, of ... Inc. (Nasdaq: AVGN ) announced today that it had ... with Avigen,s recent performance and continued destruction of shareholder value. ...
Cached Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3SCRIP, the Leading Pharmaceutical Magazine in the World Crowns Glenmark as the "Best Pharma Company in the World - SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 2Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 3Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 4Biotechnology Value Fund Delivers Letter to Board of Directors of Avigen, Inc. 5
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
(Date:7/31/2015)... 31 de julho de 2015 A 10 ... ) será realizada pela BGI de 22-25 de outubro de ... A conferência está celebrando seu 10 o. ... ICG se tornou uma das reuniões mais influentes do ... científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... tell us a lot about the way species evolve after ... exceptionally broad study conducted in part by Florida State University ... the evolutionary history of rodents calls into doubt a generally ... such as a continent, evolution leads to a dramatic increase ...
... A new study shows that immune cells outside the ... presented today at the American College of Neuropsychopharmacology (ACNP) Annual ... impact on the quality of life, health and life expectancy ... of the disorder remain something of a mystery. In ...
... between genes and the environment has been pondered at least ... mid-1800s. But until the arrival of modern genomic sequencing ... environment had on a species, genetic makeup. Now, researchers ... flies that live on opposite slopes of a unique natural ...
Cached Biology News:Study of rodent family tree puts brakes on commonly held understanding of evolution 2Study of rodent family tree puts brakes on commonly held understanding of evolution 3Peripheral immune system may regulate vulnerability to depression 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 2Environment drives genetics in 'Evolution Canyon'; discovery sheds light on climate change 3
Oxidative Stress-Inducible Protein Tyrosine Phosphatase...
... Anti-MAGE-D2/NRAGE-Like 2b GenBank ... Immunogen : peptide (C-QSQENQDTRPKVKAKK), corresponding ... human MAGE-D2/NRAGE-Like 2b Formulation: antiserum ... 30% glycerol Quality Assurance: routinely ...
Antibody specific for histone H3 acetylated at any of the five N-terminal lysine residues. Rabbit polyclonal serum. Antigen: Synthetic peptide derived from histone H3 N-terminal region, mulitpliy...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: